The Scripps Research Institute: Research to Revenue

The Scripps Research Institute

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 0 commercialization opportunities from The Scripps Research Institute and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of The Scripps Research Institute's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

46/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

9/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

27/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

1924

First Nobel

1997

First Patent

1973

First IPO

N/A

2022-2024

AI-driven diagnostics

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

1970s

Insulin Synthesis

First synthetic insulin patent

1970s

Antibody Technology

Monoclonal antibody innovations

1980s

Drug Discovery

Novel drug candidates identified

1990s

Protein Engineering

Engineered proteins commercialized

2000s

Immunotherapy Breakthrough

Cancer immunotherapy advancements

2010s

Competitive Benchmarking

The Scripps Research Institute vs. Peer Research Universities

The Scripps Research Institute vs Peers Comparison

Metric	The Scripps Research Institute (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$495M	$855M	$1,675M
New Inventions Disclosed	0	200	400
Startups Formed	2	7	10
Visibility Index	30	12	23
Licensing Revenue	$15M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. Revolutionary Antibody Engineering Platform Accelerates Drug Discovery

This platform addresses slow biologic development, enabling rapid, scalable antibody design to meet growing global demand for targeted therapeutics, reducing time and cost barriers.

2. Novel Synthetic Biology Tools for Precision Medicine

Enables scalable, customizable cellular therapies addressing complex diseases, offering competitive advantage through precise gene editing and improved patient outcomes in personalized healthcare markets.

3. Breakthrough Neurodegenerative Disease Biomarkers for Early Diagnosis

Early detection biomarkers improve treatment success rates, addressing unmet needs in Alzheimer's and Parkinson's markets with scalable diagnostic platforms for global healthcare providers.

4. Advanced Mass Spectrometry Techniques Enhance Drug Development

High-throughput, sensitive analysis accelerates pharmaceutical R&D, reducing costs and time to market, providing competitive edge in rapidly evolving biotech and pharmaceutical industries.

5. Innovative Immunotherapy Approaches Targeting Cancer Stem Cells

Targets resistant cancer populations, offering scalable therapies with superior efficacy, addressing significant oncology market challenges and unmet clinical needs in cancer treatment.

6. Cutting-Edge Computational Chemistry Platforms Optimize Drug Design

Leverages AI-driven simulations to reduce experimental costs and timelines, scaling drug discovery processes and providing a competitive advantage in pharmaceutical innovation.